{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:30:47Z","timestamp":1750307447939,"version":"3.41.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Fund of Health and Family Planning Commission of Zhejiang Province","award":["2017KY154"],"award-info":[{"award-number":["2017KY154"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The trisomy of human chromosome 21 causes Down syndrome (DS), sometimes known as congenital folly's syndrome. The survivors show apparent mental impairment, unusual facial traits, growth and development abnormalities, and various deformities, with 60 percent of the infants having miscarriages in the early stages of the fetus. Plasma micRNA (miRNA) is a new diagnostic biomarker for DS; however, its significance in first-trimester maternal plasma is unknown. As a result, the purpose of this study is to assess the diagnostic significance of the biomarker miRNA in first-trimester maternal plasma for DS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>From January 2014 until the present, blood samples were obtained from pregnant women who visited our hospital. This study included 20 eligible DS pregnancies and 20 normal pregnant women. We looked at the differential miRNA expression profile in DS maternal plasma from the first and second trimesters using miRNA microarrays. Bioinformatics technology was used to compare the particular miRNA in DS maternal plasma from the first and second trimesters and screen the miRNA co-expressed in DS maternal plasma. Meanwhile, the expression level of chosen miRNAs was verified using quantitative real-time PCR (qRT-PCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This study aims to see how useful the diagnostic biomarker miRNA in first-trimester maternal plasma is for diagnosing DS. The findings of this investigation will provide clinical evidence for the discovery of a new diagnostic biomarker miRNA in first-trimester maternal plasma for DS diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OSF regression number:<\/jats:title>\n            <jats:p>DOI 10.17605\/OSF.IO\/R49FT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028495","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T13:00:38Z","timestamp":1642770038000},"page":"e28495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The screening of diagnostic biomarker microRNA in first-trimester maternal plasma for Down syndrome"],"prefix":"10.1097","volume":"101","author":[{"given":"Fengping","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-9594","authenticated-orcid":false,"given":"Xiangkang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMra1706537","article-title":"Down syndrome","volume":"382","author":"Bull","year":"2020","journal-title":"N Engl J Med"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"e20160123","DOI":"10.1542\/peds.2016-0123","article-title":"Trends in congenital heart defects in infants with Down syndrome","volume":"138","author":"Bergstr\u00f6m","year":"2016","journal-title":"Pediatrics"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/bdr2.1589","article-title":"National population-based estimates for major birth defects, 2010\u20132014","volume":"111","author":"Mai","year":"2019","journal-title":"Birth Defects Res"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"333.e1-e8","DOI":"10.1016\/j.ajog.2007.09.045","article-title":"Perceived risk of prenatal diagnostic procedure-related miscarriage and Down syndrome among pregnant women","volume":"198","author":"Caughey","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/0002-9378(84)90530-1","article-title":"An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities","volume":"148","author":"Merkatz","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/096914139700400402","article-title":"Antenatal screening for Down's syndrome","volume":"4","author":"Wald","year":"1997","journal-title":"J Med Screen"},{"key":"R7-20250618","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1373\/clinchem.2009.139816","article-title":"First- and second-trimester ADAM12s in Down syndrome screening","volume":"56","author":"Baviera","year":"2010","journal-title":"Clin Chem"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1373\/jalm.2018.026096","article-title":"Direct immunoassay for free pregnancy-associated plasma protein A (PAPP-A)","volume":"3","author":"Tuunainen","year":"2018","journal-title":"J Appl Lab Med"},{"key":"R9-20250618","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12884-018-1930-y","article-title":"Prospective observations study protocol to investigate cost-effectiveness of various prenatal test strategies after the introduction of non-invasive prenatal testing","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T12:01:02Z","timestamp":1750248062000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028495"}},"subtitle":["A study protocol"],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028495","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"2021-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}